AmeriPath and Molecular Profiling Institute Address Cancer-Testing Dilemma with New PCA3 ProfileR(TM) Test.

PALM BEACH GARDENS, Fla. -- Finally, a longstanding medical dilemma is being addressed. AmeriPath, a leading national provider of physician-based anatomic pathology, and the Molecular Profiling Institute, a specialty reference lab, have joined forces to introduce PCA3 ProfileR(TM), a test that for the first time provides a critical new diagnostic tool for prostate cancer.

Until now, patients who showed elevated serum PSA (prostate-specific antigen) levels but had negative biopsy results were faced with a dilemma: Is the biopsy a false negative, or is the PSA elevated for reasons other than cancer? PCA3 ProfileR brings important new clarity: a positive result may indicate prostate cancer and the need for an additional biopsy; a negative result may suggest that a relatively longer time interval may be acceptable between biopsies.

"PCA3 ProfileR offers urologists a way to determine repeat biopsy intervals for patients who continue to have a PSA greater than 4 ng/ml, but who have negative biopsies," says Dr. Robert Penny, CEO, Molecular Profiling Institute. "Now, these physicians will have a dynamic new tool to potentially help guide the management of their patients who fall into this tricky area."

The overall accuracy of PCA3 ProfileR is 70%, compared to 35% for serum PSA in the study population.

AmeriPath, Inc. offers a comprehensive urologic disease management program focusing on prostate cancer, bladder cancer and kidney stone disease. AmeriPath's Molecular Profiling Institute provides additional resources and testing to enable better disease management.

For more information, visit www.AmeriPathGU.com/PCA3.

AmeriPath, a leading national provider of physician-based anatomic pathology, dermatopathology and molecular diagnostic services to physicians, hospitals, clinical laboratories and surgery centers, supports community-based medicine by helping physicians provide excellent and effective care for their patients. A team of sub-specialized pathologists and Ph.D. scientists provide medical expertise, diagnostic quality, and personal consultation services. AmeriPath's team of more than 400 highly trained, board-certified pathologists and Ph.D.-level scientists provide medical diagnostics services in outpatient laboratories owned, operated and managed by AmeriPath, as well as in hospitals and ambulatory surgical centers. AmeriPath's Web address is www.ameripath.com.

Molecular Profiling is a CLIA-certified specialty reference laboratory that helps cancer patients worldwide by applying the discoveries of the human genome project to personalized medicine. Molecular Profiling provides cutting-edge testing facilities, products, and resources for genomic and proteomic profiling and treatment of cancers and pharmaceutical services to identify populations that may respond to targeted therapies. Molecular Profiling has strategic relationships with the Translational Genomics Research Institute (TGen), the International Genomics Consortium (IGC), Scottsdale Healthcare, and AmeriPath, Inc. Molecular Profiling's Web address is www.molecularprofiling.com.